- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Interventions
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Annapolis, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 4,122
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung
- Interventions
- 212-Lead Pentixather, 203-Lead Pentixather SPECT/CT
- Drug · Diagnostic Test
- Lead sponsor
- Yusuf Menda
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
- Interventions
- Dacarbazine and bortezomib
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Richmond, Virginia
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- nimotuzumab
- Drug
- Lead sponsor
- YM BioSciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- New Port Richey, Florida • Saint Louis Park, Minnesota • Bellevue, Washington
- Conditions
- Small Cell Lung Cancer
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lung Cancer
- Interventions
- docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Non-small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Carcinoma, Cervical Cancer, Small Cell Lung Carcinoma, Squamous Cell Carcinoma of the Anus, Castration-Resistant Prostate Carcinoma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Thymoma, Thymic Carcinoma, Squamous Cell Carcinoma of the Penis, Vulvar Carcinoma, Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy, Malignant Adnexal Neoplasms, Non-squamous Cell Salivary Gland Carcinoma
- Interventions
- XmAb20717
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 12 more
- Conditions
- Mesothelin-expressing Advanced Cancers
- Interventions
- ZW171
- Drug
- Lead sponsor
- Zymeworks BC Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 4 more
- Conditions
- Lung Cancer
- Interventions
- canfosfamide hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
- Interventions
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
- Interventions
- tucatinib, trastuzumab, fulvestrant
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
- Interventions
- TR(ACE) Assay Testing
- Device
- Lead sponsor
- Biological Dynamics
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 16
- States / cities
- Encinitas, California • Oceanside, California • Santa Monica, California + 13 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
- Interventions
- PLX3397, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
- Conditions
- Lung Cancer
- Interventions
- EP-2101, incomplete Freund's adjuvant
- Biological
- Lead sponsor
- Epimmune
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 9
- States / cities
- Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Dupilumab, PD-1/PD-L1 blockade, Anakinra
- Drug
- Lead sponsor
- Thomas Marron
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- chemotherapy, Radiation
- Drug · Procedure
- Lead sponsor
- Clinical Oncology Research Associates
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Crizotinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 10
- States / cities
- Northridge, California • Redondo Beach, California • Aurora, Colorado + 6 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- IPI 504 plus Docetaxel, Placebo plus Docetaxel
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Non-squamous Cell Lung Cancer
- Interventions
- PM01183 + paclitaxel +/- bevacizumab
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- quaratusugene ozeplasmid, atezolizumab
- Biological
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Docetaxel, LY2181308
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more